PLX

Protalix BioTherapeutics, Inc.. operates in the biological products, (no diagnostic substances) industry. listed on NYSE. headquartered in HACKENSACK, NJ.

Protalix BioTherapeutics, Inc. (PLX) is publicly traded on NYSE within the Healthcare sector , specifically in the Biological Products, (No Diagnostic Substances) industry. The company is headquartered in HACKENSACK, NJ.

Business classification: According to SEC filings, Protalix BioTherapeutics, Inc. falls under SIC code 2836 — Biological Products, (No Diagnostic Substances). This classification helps investors compare the company against peers in similar regulatory and operational environments.

Sector outlook: Companies in the Healthcare sector typically share exposure to similar macroeconomic factors — interest rates, regulatory shifts, and consumer demand patterns specific to this industry vertical. Investors evaluating PLX should benchmark against other Healthcare stocks for comparative analysis.

Industry-specific factors: The Biological Products, (No Diagnostic Substances) industry has specific competitive dynamics — market share concentration, supply chain dependencies, and capital intensity that affect valuation. Compare PLX with peer companies in Biological Products, (No Diagnostic Substances) to assess relative positioning.

Regulatory disclosures: With CIK 0001006281, Protalix BioTherapeutics, Inc. files mandatory disclosures with the U.S. Securities and Exchange Commission. These include 10-K annual reports, 10-Q quarterly reports, and 8-K material event filings — accessible via the official SEC EDGAR portal for fundamental research.

This page is for educational and research purposes only and does not constitute investment advice. Always conduct independent due diligence and consult a licensed financial advisor before making investment decisions.